Visfatin As a Predictor for Growth of Fetus and Infant

Overview

Journal Turk J Obstet Gynecol

Specialty Gynecology & Obstetrics

Date 2018 Jul 5

PMID 29971183

Citations 3

Authors

Ashraf Saber Mashhad Taraqi

Najmeh Tehranian

Shiva Pourali Roudbaneh

Matin Sadat Esmaeilzadeh

Anoshirvan Kazemnejad

Marzieh Faghani Aghoozi

Somayeh Yousefi

Affiliations

Soon will be listed here.

Abstract

Objective: Visfatin is an adipocytokine that functions as an enzyme and a growth factor to investigate the relationship between serum visfatin and the fetus's anthropometric markers up to a year after birth.

Materials And Methods: Forty-one eligible pregnant women in their first trimester were divided and matched in terms of body mass index (BMI) before pregnancy into normal and higher than normal BMI groups, A and B. Serum visfatin levels were measured during 6-12 and 15-20 weeks of gestation using ELISA.

Results: The infants were followed up for a mean duration of 10.19±2.83 months. In group A, there was a strong positive relationship between birth head circumference and the first (p=0.054, r=0.580) and second trimester visfatin levels (p=0.051, r=0.530). In group B, second trimester visfatin levels correlated negatively with birth length (p=0.015, r=-0.523) and infant's head circumference (p=0.050, r=-0.392). In a separate study on group B, visfatin levels in the first and second trimesters showed a significant negative correlation with infant's weight. A significant correlation was observed between the first and second trimesters visfatin level with infant's height in both groups, such that this relationship was positive in group A and negative in group B. Linear regression analysis revealed that first and second trimester visfatin levels were significant independent predictors of infant's weight in group B and infant's height in both groups. Second trimester visfatin level was a significant predictor of birth height in group B.

Conclusion: Maternal serum visfatin level shows a relationship with fetal and infant anthropometric indicators, with different effects in the two groups, suggesting visfatin dysfunction in the overweight group before pregnancy.

Citing Articles

Impact of Gestational Diabetes Mellitus on Fetal Growth and Nutritional Status in Newborns.

Karcz K, Krolak-Olejnik B Nutrients. 2024; 16(23).

PMID: 39683486 PMC: 11643953. DOI: 10.3390/nu16234093.

Novel Biomolecules in the Pathogenesis of Gestational Diabetes Mellitus.

Ruszala M, Niebrzydowska M, Pilszyk A, Kimber-Trojnar Z, Trojnar M, Leszczynska-Gorzelak B Int J Mol Sci. 2021; 22(21).

PMID: 34769010 PMC: 8584125. DOI: 10.3390/ijms222111578.

The Role of the Adipokines in the Most Common Gestational Complications.

Gutaj P, Sibiak R, Jankowski M, Awdi K, Bryl R, Mozdziak P Int J Mol Sci. 2020; 21(24).

PMID: 33321877 PMC: 7762997. DOI: 10.3390/ijms21249408.

References

Ma Y, Cheng Y, Wang J, Cheng H, Zhou S, Li X . The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes. Diabetes Res Clin Pract. 2010; 90(1):60-5. DOI: 10.1016/j.diabres.2010.06.010. View

Dietrich M, Antunes C, Geliang G, Liu Z, Borok E, Nie Y . Agrp neurons mediate Sirt1's action on the melanocortin system and energy balance: roles for Sirt1 in neuronal firing and synaptic plasticity. J Neurosci. 2010; 30(35):11815-25. PMC: 2965459. DOI: 10.1523/JNEUROSCI.2234-10.2010. View

He X, He J, Shi Y, Pi C, Yang Y, Sun Y . Nicotinamide phosphoribosyltransferase (Nampt) may serve as the marker for osteoblast differentiation of bone marrow-derived mesenchymal stem cells. Exp Cell Res. 2017; 352(1):45-52. DOI: 10.1016/j.yexcr.2017.01.021. View

Zhang T, Kraus W . SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions. Biochim Biophys Acta. 2009; 1804(8):1666-75. PMC: 2886162. DOI: 10.1016/j.bbapap.2009.10.022. View

Haider D, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M . The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia. 2006; 49(8):1909-14. DOI: 10.1007/s00125-006-0303-7. View

Cekmez F, Pirgon O, Tanju A, Ipcioglu O . Cord plasma concentrations of visfatin, adiponectin and insulin in healthy term neonates: positive correlation with birthweight. Int J Biomed Sci. 2013; 5(3):257-60. PMC: 3614788. View

Mazaki-Tovi S, Romero R, Kusanovic J, Vaisbuch E, Erez O, Than N . Visfatin in human pregnancy: maternal gestational diabetes vis-à-vis neonatal birthweight. J Perinat Med. 2008; 37(3):218-31. PMC: 3504974. DOI: 10.1515/JPM.2009.053. View

Sasaki T, Kikuchi O, Shimpuku M, Susanti V, Yokota-Hashimoto H, Taguchi R . Hypothalamic SIRT1 prevents age-associated weight gain by improving leptin sensitivity in mice. Diabetologia. 2013; 57(4):819-31. PMC: 3940852. DOI: 10.1007/s00125-013-3140-5. View

Jukarainen S, Heinonen S, Ramo J, Rinnankoski-Tuikka R, Rappou E, Tummers M . Obesity Is Associated With Low NAD(+)/SIRT Pathway Expression in Adipose Tissue of BMI-Discordant Monozygotic Twins. J Clin Endocrinol Metab. 2015; 101(1):275-83. DOI: 10.1210/jc.2015-3095. View

10.

Yonezawa T, Haga S, Kobayashi Y, Takahashi T, Obara Y . Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway. FEBS Lett. 2006; 580(28-29):6635-43. DOI: 10.1016/j.febslet.2006.11.014. View

11.

Li Y, He J, He X, Li Y, Lindgren U . Nampt expression increases during osteogenic differentiation of multi- and omnipotent progenitors. Biochem Biophys Res Commun. 2013; 434(1):117-23. DOI: 10.1016/j.bbrc.2013.02.132. View

12.

Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, Recasens M, Esteve E, Casamitjana R . Serum visfatin increases with progressive beta-cell deterioration. Diabetes. 2006; 55(10):2871-5. DOI: 10.2337/db06-0259. View

13.

Malamitsi-Puchner A, Briana D, Boutsikou M, Kouskouni E, Hassiakos D, Gourgiotis D . Perinatal circulating visfatin levels in intrauterine growth restriction. Pediatrics. 2007; 119(6):e1314-8. DOI: 10.1542/peds.2006-2589. View

14.

Bienertova-Vasku J, Bienert P, Zlamal F, Tomandl J, Tomandlova M, Dostalova Z . Visfatin is secreted into the breast milk and is correlated with weight changes of the infant after the birth. Diabetes Res Clin Pract. 2011; 96(3):355-61. DOI: 10.1016/j.diabres.2011.06.009. View

15.

Sonoli S, Shivprasad S, Prasad C, Patil A, Desai P, Somannavar M . Visfatin--a review. Eur Rev Med Pharmacol Sci. 2011; 15(1):9-14. View

16.

Mazaki-Tovi S, Romero R, Kwon Kim S, Vaisbuch E, Kusanovic J, Erez O . Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA?. J Matern Fetal Neonatal Med. 2009; 23(8):857-68. PMC: 3554253. DOI: 10.3109/14767050903301017. View

17.

Herskovits A, Guarente L . SIRT1 in neurodevelopment and brain senescence. Neuron. 2014; 81(3):471-83. PMC: 4040287. DOI: 10.1016/j.neuron.2014.01.028. View

18.

Valsamakis G, Papatheodorou D, Margeli A, Bakoulas V, Kapantais E, Papassotiriou I . First trimester maternal BMI is a positive predictor of cord blood c-peptide levels while maternal visfatin levels is a negative predictor of birth weight. Hormones (Athens). 2014; 13(1):87-94. DOI: 10.1007/BF03401324. View

19.

Ng F, Wijaya L, Tang B . SIRT1 in the brain-connections with aging-associated disorders and lifespan. Front Cell Neurosci. 2015; 9:64. PMC: 4353374. DOI: 10.3389/fncel.2015.00064. View

20.

Mastorakos G, Valsamakis G, Papatheodorou D, Barlas I, Margeli A, Boutsiadis A . The role of adipocytokines in insulin resistance in normal pregnancy: visfatin concentrations in early pregnancy predict insulin sensitivity. Clin Chem. 2007; 53(8):1477-83. DOI: 10.1373/clinchem.2006.084731. View